Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study

The Saudi Food and Drug Authority (SFDA) approved sodium-glucose cotransporter-2 (SGLT2) inhibitors in 2018. The efficacy and safety of empagliflozin (EMPA) have been confirmed in the U.S., Europe, and Japan for patients with type 2 diabetes mellitus (T2DM); however, analogous evidence is lacking fo...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical medicine 2022-08, Vol.11 (16), p.4769
Hauptverfasser:	Althobaiti, Fahad M, Alsanosi, Safaa M, Falemban, Alaa H, Alzahrani, Abdullah R, Fataha, Salma A, Salih, Sara O, Alrumaih, Ali M, Alotaibi, Khalid N, Althobaiti, Hazim M, Al-Ghamdi, Saeed S, Ayoub, Nahla
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Antidiabetics Armed forces Clinical medicine Confidence intervals Diabetes FDA approval Glucose Insulin Liver Observational studies Pulmonary arteries Sample size Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!